Bayer (BAYRY) announced encouraging detailed results from the late-stage FINEARTS-HF study on finerenone. Finerenone is marketed as Kerendia or Firialta in some countries. The drug is approved for the treatment of adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D) in more than 90 countries worldwide, including China, Europe, Japan and the United States. It is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist that has been shown to block the harmful eff ...